Skip to main content

Tonix Pharmaceuticals Holding Corp.

corporate_fare Company Profile

Tonix Pharmaceuticals Holding Corp.

TNXP·NASDAQ·Life Sciences·CIK 0001430306

Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company that develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra, which are used for the treatment of acute migraine with or without aura in adults. Tonix Pharmaceuticals Holding Corp. is developing several product candidates, including TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for cocaine intoxication; and TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection and treat autoimmune conditions. Other development programs include TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; TNX-2900, an intranasal oxytocin potentiated with magnesium for Prader-Willi syndrome; and TNX-1900, an intranasal potentiated oxytocin for binge eating disorder, adolescent obesity, bone health in pediatric autism, and arginine-vasopressin deficiency. The company is also developing TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. The company was founded in 2007 and is based in Berkeley Heights, New Jersey.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for TNXP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for TNXP spans 8-K, 10-Q.

Recent high-impact activity:

  • Tonix Sues Dr. Reddy's on TONMYA Patents, Triggering 30-Month FDA Approval Stay
  • Tonix Q3: TONMYA Sales $15.0M, Net Loss $53.3M, Going-Concern Warning
  • Tonix Q3: TONMYA Sales $15.0M, Net Loss Widens to $53.3M, Runway to Early Q3 2027
  • Tonix Q3 TONMYA Sales Hit $15M, But Net Loss Widens to $53.3M
  • Phase 3 Data Show TONMYA Beats Placebo on Pain and FIQR at Week 14

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$13.11M
Net Income
-$124.02M
Diluted EPS
-$14.57
Op. Cash Flow
-$99.84M
Free Cash Flow
-$103.21M
Gross Profit
$6.47M
Operating Income
-$125.7M
Cash & Equivalents
$207.64M
Debt / Equity
0.00×
Net Margin
-9.46×
Shares Outstanding
12.79M sh
Source: 10-K · filed 2026-03-12 · accession 0001999371-26-005730

Short Interest & Short Volume

4.14 days to cover

FINRA reported short interest of 3,318,461 shares in TNXP as of the October 30, 2026 settlement, a 12.9% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 19, 2026, 56.5% of TNXP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,318,461 shares as of October 30, 2026
Change vs prior period▲ 12.9%
Days to cover4.14 at avg daily volume of 802,002
Daily short volume (FINRA facilities)56.5% of 439,485 shares on November 19, 2026
5-day average short volume52.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with T →
$2.59 +1.54% today
52-week range · as of 2026-11-13 $2.59 – $20.56
Market cap
$49.55M
Volume
890.3K (0.8× avg)
3-mo avg 1.1M
Live data · 2026-11-20 13:09 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed TNXP - Latest Insights

TNXP
Nov 13, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.59 info
Change: -$0.4007 (-13%) info
Market Cap: $49.55M info
TNXP
Nov 09, 2026, 8:25 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $2.59 info
Change: -$1.41 (-35%) info
Market Cap: $49.55M info
TNXP
Nov 09, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $2.59 info
Change: -$1.51 (-37%) info
Market Cap: $49.55M info
TNXP
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $2.59 info
Change: -$1.76 (-40%) info
Market Cap: $49.55M info
TNXP
Oct 27, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $2.59 info
Change: -$2.77 (-52%) info
Market Cap: $49.55M info
TNXP
Oct 15, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.42
Real-time Price: $2.59 info
Change: -$3.83 (-60%) info
Market Cap: $49.55M info
TNXP
Oct 02, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.93
Real-time Price: $2.59 info
Change: -$6.34 (-71%) info
Market Cap: $49.55M info
TNXP
Sep 22, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.78
Real-time Price: $2.59 info
Change: -$8.19 (-76%) info
Market Cap: $49.55M info
TNXP
Aug 10, 2026, 8:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.80
Real-time Price: $2.59 info
Change: -$9.21 (-78%) info
Market Cap: $49.55M info
TNXP
Aug 10, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.75
Real-time Price: $2.59 info
Change: -$9.16 (-78%) info
Market Cap: $49.55M info
TNXP
Aug 10, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.75
Real-time Price: $2.59 info
Change: -$9.16 (-78%) info
Market Cap: $49.55M info
TNXP
Aug 03, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.14
Real-time Price: $2.59 info
Change: -$7.55 (-74%) info
Market Cap: $49.55M info
TNXP
Jul 13, 2026, 7:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.20
Real-time Price: $2.59 info
Change: -$10.61 (-80%) info
Market Cap: $49.55M info
TNXP
Jul 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.06
Real-time Price: $2.59 info
Change: -$10.47 (-80%) info
Market Cap: $49.55M info
TNXP
Jun 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.22
Real-time Price: $2.59 info
Change: -$10.63 (-80%) info
Market Cap: $49.55M info
TNXP
Jun 08, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.42
Real-time Price: $2.59 info
Change: -$8.83 (-77%) info
Market Cap: $49.55M info
TNXP
Jun 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.42
Real-time Price: $2.59 info
Change: -$8.83 (-77%) info
Market Cap: $49.55M info
TNXP
May 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.96
Real-time Price: $2.59 info
Change: -$10.37 (-80%) info
Market Cap: $49.55M info
TNXP
May 15, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.84
Real-time Price: $2.59 info
Change: -$11.25 (-81%) info
Market Cap: $49.55M info
TNXP
May 11, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.31
Real-time Price: $2.59 info
Change: -$10.72 (-81%) info
Market Cap: $49.55M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets